In an illustration of the vital importance of pharmacogenomics in risk reduction, one study showed that the combination of TPMT and NUDT15 mutations accounted for ~50% of severe thiopurine-induced leukopenia (32). This evidence concerns the gene TPMT and Decreased total leukocyte count.